Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051155 · ClinicalTrials.gov registry record · Phase 3
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
A Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00051155 is a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Alcon Research. The trial reports 1 study location across 1 state.
The verdict
NCT00051155, a Phase 3 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Travoprost (0.004%)
- DRUG Latanoprost (0.005%)/Timolol (0.5%)
Study Locations (1)
Texas
- Europe - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Est. Completion | 2004-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051155
The ClinicalTrials.gov registry entry for NCT00051155 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Travoprost (0.004%) is the first listed.
NCT00051155 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00051155 about?
NCT00051155 is a clinical study titled "A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)". To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00051155?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-01. Estimated completion is 2004-07.
What conditions does trial NCT00051155 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT00051155?
The interventions under investigation include: Travoprost (0.004%) (DRUG), Latanoprost (0.005%)/Timolol (0.5%) (DRUG).
Who is sponsoring clinical trial NCT00051155?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051155 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.